; (5) identification of all external experts with expertise in rare diseases and conditions who are consulted in connection with, or who otherwise participate in, each review of an application described in paragraph (1); and (6) the status of each application described in paragraph (1). (b) Public availability The Secretary shall make each report under subsection (a) available to the public, including by posting the report on the website of the Food and Drug Administration. . (b) Study on European Union safety and efficacy reviews of drugs for rare diseases and conditions (1) In general The Comptroller General of the United States shall conduct a study on European Union safety and efficacy reviews of drugs for rare diseases and conditions, including— (A) any differential prevalence-based mechanisms; and (B) consideration and use of supplemental data submitted during the review process, including data associated with open label extension studies and expanded access programs. (2) Report Not later than 1 year after the date of enactment of this Act, the Comptroller General shall— (A) complete the study under paragraph (1); (B) submit a report on the results of such study to the Congress